We first determined the expression levels of EP300 and CREBBP across a panel of melanoma cell lines that were either sensitive or resistant to BRAFi therapy and found that cell lines that were sensitive to inhibitor therapy had increased EP300 levels (Fig. 7a). Here, EP300 is linked to melanoma.